# Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

> **NCT04506645** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 90 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** REGN5381
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04506645
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2022-12-14
- **Final completion:** 2022-12-14
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2022-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04506645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04506645, "Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04506645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*